An NIH-funded partnership between ISCRM faculty member Dr. Daniel Yang and Dr. Lea Starita in the UW Department of Genome Sciences will use an innovative gene editing technology to sequence large numbers of variants of a mutation associated with hypertrophic cardiomyopathy. Read More
Researchers at UW and UCSD use a multiscale modeling tool show how small infusions of myosin can have a big impact on the whole heart. Read More
A new 3D modeling tool developed by the Sniadecki Lab and Dr. Tracy Popwics in the School of Dentistry could lead to regenerative therapies for periodontal diseases. Read More
ISRCRM faculty member David Baker has been awarded the 2024 Nobel Prize in Chemistry for computational protein design. Read More
A new gene therapy treatment for Duchenne muscular dystrophy (DMD) shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in the future, repairing those muscles. Read More
Kelly Stevens and Lola Eniola-Adefeso at the University of Michigan are co-leaders of a new NIH-funded center that will spur biomaterials translational solutions and bring together traditional, nontraditional, and historically excluded biomaterials researchers. Read More
UW researchers have used computer-designed proteins to direct human stem cells to form new blood vessels in the lab, offering new hope for repairing damaged hearts, kidneys, and other organs. Read More
ISCRM Associate Director Nate Sniadecki, PhD, Professor of Mechanical Engineering and Hichem Tasfaout, PhD, Acting Assistant Professor, Neurology have received prestigious awards from the John H. Tietze Foundation Trust that will help fuel promising research underway in their labs. Read More
An NIH-funded collaboration involving ISCRM researchers has published a study describing how complementary areas of expertise produced new insights about hypertrophic cardiomyopathy at the protein, cell, and tissue levels. Read More
In a new study published in Cell Stem Cell, the Freedman Lab shows that a drug known to be safe in humans inhibits the growth of cysts in gene-edited organoids with polycystic kidney disease. Read More
